CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next.

As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed hands at about $56.88 per share, implying a market value just under $5.9 billion. The stock sits well above its 52‑week low near $30 but below its high around $78, underlining just how wild the ride has been for gene‑editing investors. ^[1]

Below is a rundown of the latest news, institutional moves, analyst forecasts and technical signals as of 7 December 2025, plus what they might mean for CRISPR stock and the broader CRISPR sector.

1. Where CRISPR Therapeutics stock stands today

According to recent market data:

Last close: $56.88
Intraday range (last session): roughly $56.0 – $58.9
Market cap: ≈ $5.9 billion
Beta: around 1.7 (meaning it tends to move more than the overall market) ^[2]
52‑week range: ~$30.04 – $78.48 ^[3]

That places CRSP in the “not cheap, not bubble‑peak” zone: a mid‑cap biotech with a first‑in‑class approved product and a pipeline that could move it meaningfully up or down from here.

Over the past week, CRSP has actually risen about 9%, according to a weekend overview from TipRanks, even as the company reported another sizable loss for the third quarter. ^[4] So the stock is rallying despite numbers that look ugly at first glance.

2. Fresh news on 7 December 2025: institutional buying and momentum

Big public pension fund buys in

On 7 December 2025, MarketBeat reported that the State Board of Administration of Florida Retirement System opened a new position in CRISPR Therapeutics, purchasing 21,361 shares valued at roughly $1.04 million. ^[5]

That filing was accompanied by a list of other institutional investors that either initiated or expanded positions in 2025, and the article notes that about 69% of CRSP shares are now held by institutions and hedge funds. ^[6] For a once‑esoteric gene‑editing story, that’s a sign CRSP has migrated firmly into mainstream biotech portfolios.

Price action vs. fundamentals

That same MarketBeat summary pegs CRSP’s 1‑year low and high at roughly $30 and $78 respectively and emphasizes the stock’s negative earnings, with a trailing P/E that is, unsurprisingly for a development‑stage biotech, deeply below zero. ^[7]

Meanwhile, a TipRanks weekend piece highlights:

Net loss in Q3 2025: about $106.4 million, wider than the prior‑year period
Quarterly revenue: only $0.89 million, mostly from grants
Yet, a “Moderate Buy” consensus and a price target around $71.8 per share from its analyst set. ^[8]

So institutions are buying a business that is currently bleeding cash but sitting on what could be platform‑level technology.

3. Q3 2025 results: deep losses, deep pipeline, big cash pile

CRISPR’s third‑quarter 2025 earnings, reported on 10 November 2025, look like textbook high‑R&D biotech:

Cash, cash equivalents and marketable securities: about $1.94 billion as of 30 September 2025, up slightly from year‑end 2024. ^[9]
R&D expenses: fell to $58.9 million in Q3 2025 from $82.2 million a year earlier, reflecting lower external manufacturing and research costs and some reduction in employee‑related expenses. ^[10]
G&A expenses: roughly flat year‑on‑year at ~$16.9 million. ^[11]
Collaboration expense, net: jumped sharply to about $57.1 million, linked to how costs are shared with Vertex on their joint programs, especially Casgevy. ^[12]
Net loss:$106.4 million vs $85.9 million in Q3 2024. ^[13]

MarketBeat’s summary adds that Q3 revenue of $0.89 million badly missed a consensus expectation near $8.7 million, and that analysts expect full‑year 2025 EPS around –$5.16. ^[14] Other analyst compilers expect losses to continue into 2026, though narrowing. ^[15]

In other words: the balance sheet is strong, but the P&L is intentionally ugly as the company spends heavily to build a multi‑program gene‑editing platform.

4. Casgevy: the flagship gene‑editing product keeps expanding

The stock story is tied tightly to Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9‑based therapy approved in the U.S. for sickle cell disease (SCD) and transfusion‑dependent β‑thalassemia (TDT), co‑developed with Vertex Pharmaceuticals. ^[16] Vertex commercializes Casgevy and splits costs and profits 60/40 with CRISPR Therapeutics. ^[17]

Q3 2025 business update: ramping, but still early

CRISPR’s November business update gives a detailed snapshot of the Casgevy rollout: ^[18]

Regulatory footprint: Casgevy is now approved in the U.S., EU, U.K., Canada, Switzerland, Saudi Arabia, Bahrain, Qatar and the UAE for eligible SCD and TDT patients 12 and older.
Eligible patient pool: more than 60,000 patients across these markets, including about 37,000 in North America and Europe.
Patient flow through the system (since launch through 30 Sept 2025):
- ~165 patients have completed initial cell collection (50 of them in Q3 alone).
- 39 patients have received Casgevy infusions (10 in Q3).
- Nearly 300 patients have been referred to authorized treatment centers (ATCs).
Operational ramp: the number of ATCs initiating multiple patients is rising; by the end of Q3, 25 centers had started more than five patients each.

Vertex now expects over $100 million in Casgevy revenue for 2025, with “significant growth” projected for 2026 as more centers ramp and reimbursement expands. ^[19] That revenue is booked at Vertex, but CRISPR gets 40% of the profit stream.

Some analysts, including a recent Seeking Alpha note (access‑restricted but visible in snippets), have expressed concern that Casgevy’s launch is slower and less profitable than early bulls hoped, even as pipeline data look stronger, leading them to sit at a Hold rating on CRSP. ^[20]

New pediatric data could expand the market

On 6 December 2025, Reuters reported that Vertex’s gene therapy freed children aged 5–11 with SCD from painful vaso‑occlusive crises for at least 12 months, and made similarly aged TDT patients transfusion‑free over the same period. ^[21] Specifically:

In a late‑stage trial, four SCD patients aged 5–11 who had enough follow‑up time were free of vaso‑occlusive crises for at least a year, with the longest case approaching two years.
Twelve TDT patients in that age group achieved transfusion independence, again up to nearly two years of follow‑up. ^[22]

Vertex plans to file for regulatory expansion to include 5–11‑year‑olds in the first half of 2026, backed by a priority voucher to speed review. ^[23]

For CRISPR Therapeutics, that’s potentially a larger addressable population and more durable royalty/profit‑share economics—though it also comes with the usual gene‑therapy risks, underscored by one TDT patient’s death in the trial due to chemotherapy‑related liver complications (busulfan conditioning, not the edit itself). ^[24]

5. CTX310: CRISPR jumps from rare diseases to cholesterol

While Casgevy proves CRISPR can cure rare blood disorders, the company is now aiming squarely at mainstream cardiovascular disease.

In November, Phase 1 data for CTX310, an in‑vivo CRISPR therapy that targets the ANGPTL3 gene in the liver, were presented at the American Heart Association (AHA) meeting and published in the New England Journal of Medicine. ^[25]

Key points from CRISPR’s update and a widely covered Wired feature: ^[26]

15 participants with uncontrolled LDL cholesterol and triglycerides received a one‑time intravenous CTX310 infusion.
At the highest dose, LDL cholesterol and triglycerides fell by about 50% on average within two weeks, with the effect maintained for the 60‑day observation period of the trial.
Side effects were mostly mild and transient (e.g., back pain, nausea), with one death in a low‑dose cohort attributed to severe pre‑existing heart disease rather than the therapy itself.

CRISPR plans to move CTX310 into Phase 1b studies focused on severe hypertriglyceridemia and mixed dyslipidemia in 2026. ^[27]

From a stock‑valuation angle, CTX310 matters because cholesterol and triglyceride disorders are common, chronic and huge markets. Getting even a sliver of statin‑and‑PCSK9 territory with a one‑and‑done gene editor would be materially different from selling a handful of ultra‑rare disease cures.

6. Analyst ratings and price targets: bullish, but not unanimous

Wall Street appears to like CRISPR Therapeutics—just not quite as much as the most excited retail bulls.

Across multiple data providers:

MarketBeat:
- Analyst mix: 11 Buy, 8 Hold, 2 Sell
- Average rating: effectively a “Hold”
- Consensus 12‑month price target: about $67.4 per share. ^[28]
TipRanks:
- Describes the consensus as a “Moderate Buy”
- Highlights a price target of about $71.8. ^[29]
Public.com:
- 17 analysts in its dataset
- Overall “Buy” rating
- 2025 price prediction:$71 per share. ^[30]
Moomoo (Japanese portal):
- 14 analysts have issued ratings in the last three months
- Roughly 86% bullish, ~14% neutral, 0% bearish
- Average target:$78.67 (range $56–$105). ^[31]
MLQ.ai:
- Compiles 37 analysts over the last three months
- Overall rating: Buy
- Average 12‑month target:$66.33, implying around 24% upside from roughly $56.88. ^[32]
TickerNerd:
- Uses data from 38 Wall Street analysts
- Labels sentiment “bullish”
- Median price target:$76, with a range from $32 to $268, implying roughly 33–34% upside from current levels. ^[33]

If you blend those together, you get a rough picture:

Wall Street’s center of gravity is clustered in the mid‑$60s to mid‑$70s, with 20–40% upside from current levels, but with extremely wide disagreement between bears and super‑bulls.

Analysts also expect continued losses in 2025 and 2026, though several sources show consensus that EPS should improve meaningfully over that period. ^[34]

7. Technical view: strong RS rating, but AI says “strong sell”

On the technical side, CRSP is sending mixed signals.

Relative strength and breakout watchers

Investor’s Business Daily (IBD) recently noted that CRISPR Therapeutics’ Relative Strength (RS) Rating—a score of price performance over the past 52 weeks—has climbed into the 80s, placing the stock among the market’s better performers. ^[35]

However, IBD also stresses that CRSP is not in a classic “buy zone”, as defined by its chart patterns, and suggests watching for a consolidation and breakout rather than chasing the move. ^[36]

Algorithmic technical analysis: short‑term caution

Intellectia, an AI‑driven technical analysis platform, currently labels CRSP a “Strong Sell candidate” on a short‑term technical basis, even while acknowledging an uptrend since late November: ^[37]

Highlights from its 7 December 2025 view:

Last close: $56.88 on 5 December, down about 2.2% on the day. ^[38]
Signals: 2 buy signals vs 5 sell signals, with a negative overall technical score. ^[39]
Moving averages:
- Short‑term averages look constructive, but the 20‑day SMA is still below the 60‑day, which Intellectia interprets as a bearish mid‑term trend. ^[40]
Support and resistance levels:
- Resistance around $61.08 and $65.57
- Support around $46.56 and $42.07; breaking below those levels would generate new sell signals in its model. ^[41]
Short selling: a short‑sale ratio of ~26% as of 5 December, suggesting a meaningful cohort betting against the stock. ^[42]

So you have a strange combination: fundamental analysts mostly bullish, technical AI models cautious, and momentum tools like IBD’s RS rating flashing strength.

For a volatile biotech, that tension is… normal.

8. CRISPR stock in the wider gene‑editing boom

CRISPR Therapeutics isn’t operating in a vacuum; it’s one of several big players in a rapidly growing gene‑editing ecosystem.

A recent industry roundup from Labiotech estimates that the global CRISPR market was worth roughly $3.8 billion in 2024 and could reach about $7.5 billion by 2029, with CASGEVY’s success acting as a major validation for the field. ^[43]

Other CRISPR‑focused companies—such as Intellia Therapeutics and Editas Medicine—are also pushing forward, especially in hereditary angioedema, blindness and other genetic diseases. ^[44]

An Investor’s Business Daily analysis recently contrasted CRISPR and Intellia:

CRISPR impressed investors with CTX310’s lipid‑lowering data and growing expectations that CASGEVY sales could top $100 million.
Intellia reported strong hereditary angioedema results but faced safety concerns after a patient death in another program, leaving some analysts more cautious on that name. ^[45]

The key takeaway: the gene‑editing theme is very much alive, but regulatory and safety scrutiny is intense, and bad news for one player can splash onto the whole group.

9. Main risks for CRSP heading into 2026

Even with real‑world patients benefiting from Casgevy and exciting cardiovascular data, CRISPR Therapeutics is far from a “safe” stock. Key risk themes include:

Commercial risk on Casgevy
- Multiple commentaries (including a 2025 Seeking Alpha note and coverage around Vertex’s Q3 results) describe the Casgevy launch as slower and less economically attractive than the most optimistic projections, even as authorized centers and referrals increase. ^[46]
- High treatment complexity, conditioning toxicity and payer negotiations all limit instant hockey‑stick adoption.
Pipeline execution risk
- CTX310’s cholesterol‑lowering data are early and drawn from only 15 patients in Phase 1; long‑term safety and durability will take years to prove. ^[47]
- Other programs (CTX320, CTX460, CTX340, SRSD107, CTX112, etc.) are in early‑stage clinical or preclinical development; historically, many such programs fail or get delayed. ^[48]
Regulatory and safety risk
- gene editing, especially in the liver, carries off‑target and liver‑toxicity concerns. The sector has already seen trial pauses and a patient death in another company’s program, which regulators and investors are watching closely. ^[49]
Valuation and volatility
- With a beta above 1.7, CRSP is more volatile than the market. ^[50]
- Price targets range absurdly widely (from the low $30s to well over $200 in some datasets), underscoring just how uncertain the long‑term scenario is. ^[51]

In short: this is not a bond proxy; it’s a leveraged bet on CRISPR biology and execution.

10. Bottom line on CRISPR stock as of 7 December 2025

Putting all of this together, the CRISPR Therapeutics (CRSP) setup on 7 December 2025 looks like this:

The science and pipeline
- Proven, first‑in‑class gene‑editing therapy (Casgevy) with expanding indications and geographies. ^[52]
- Early‑stage but eye‑catching CTX310 data that push CRISPR from rare diseases toward common cardiovascular conditions. ^[53]
- A broad in‑vivo and cell‑therapy pipeline in autoimmune disease, oncology and cardiovascular indications. ^[54]
The financial position
- Nearly $2 billion in cash and marketable securities, enough to fund years of development at current burn rates. ^[55]
- Persistent and intentional net losses as the company prioritizes R&D and collaboration spending. ^[56]
The market’s view
- Most fundamental analysts: mildly to strongly bullish, with consensus 12‑month targets in the mid‑$60s to mid‑$70s, implying respectable upside from current levels. ^[57]
- Technical/AI models: short‑term cautious to bearish, highlighting heavy short interest, overhead resistance in the low‑to‑mid $60s, and the possibility of a pullback if support near the mid‑$40s breaks. ^[58]

For investors, CRSP today is essentially a leveraged play on whether CRISPR gene editing can scale from rare diseases into mainstream medicine—and whether CRISPR Therapeutics specifically ends up owning a large enough share of that future.

It’s a field where biology, regulation, and market psychology are all moving targets, so any position in CRSP sits firmly in the “high risk, potentially high reward” corner of a portfolio. None of this is personal investment advice; it’s a snapshot of where the facts, forecasts and debates stand on 7 December 2025. The next clinical data drop or regulatory decision could move the story dramatically in either direction.